103 related articles for article (PubMed ID: 33314199)
21. Characteristics and Outcomes of Small Cell Lung Cancer Detected by CT Screening.
Thomas A; Pattanayak P; Szabo E; Pinsky P
Chest; 2018 Dec; 154(6):1284-1290. PubMed ID: 30080997
[TBL] [Abstract][Full Text] [Related]
22. Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up.
Wu WY; Törnberg S; Elfström KM; Liu X; Nyström L; Jonsson H
Breast Cancer Res; 2018 Dec; 20(1):153. PubMed ID: 30558679
[TBL] [Abstract][Full Text] [Related]
23. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
Blom J; Törnberg S
J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
[TBL] [Abstract][Full Text] [Related]
24. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
[TBL] [Abstract][Full Text] [Related]
25. Do competing causes of mortality contribute to overdiagnosis in lung cancer screening?
Durham DD; Croswell JM; Marcus PM
Lung Cancer; 2021 Mar; 153():21-24. PubMed ID: 33445120
[TBL] [Abstract][Full Text] [Related]
26. Estimating age group-dependent sensitivity and mean sojourn time in colorectal cancer screening.
Sung NY; Jun JK; Kim YN; Jung I; Park S; Kim GR; Nam CM
J Med Screen; 2019 Mar; 26(1):19-25. PubMed ID: 30261804
[TBL] [Abstract][Full Text] [Related]
27. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Oken MM; Marcus PM; Hu P; Beck TM; Hocking W; Kvale PA; Cordes J; Riley TL; Winslow SD; Peace S; Levin DL; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Dec; 97(24):1832-9. PubMed ID: 16368945
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
29. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial.
Tammemägi MC; Ten Haaf K; Toumazis I; Kong CY; Han SS; Jeon J; Commins J; Riley T; Meza R
JAMA Netw Open; 2019 Mar; 2(3):e190204. PubMed ID: 30821827
[TBL] [Abstract][Full Text] [Related]
30. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
31. [Tailored Breast Screening Trial (TBST)].
Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
[TBL] [Abstract][Full Text] [Related]
32. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
[TBL] [Abstract][Full Text] [Related]
33. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.
Shen Y; Yang Y; Inoue LY; Munsell MF; Miller AB; Berry DA
J Natl Cancer Inst; 2005 Aug; 97(16):1195-203. PubMed ID: 16106024
[TBL] [Abstract][Full Text] [Related]
34. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
[TBL] [Abstract][Full Text] [Related]
35. Reviewing interval cancers: time well spent?
Gower-Thomas K; Fielder HM; Branston L; Greening S; Beer H; Rogers C
Clin Radiol; 2002 May; 57(5):384-8. PubMed ID: 12014936
[TBL] [Abstract][Full Text] [Related]
36. A simple way to measure the burden of interval cancers in breast cancer screening.
Andersen SB; Törnberg S; Lynge E; Von Euler-Chelpin M; Njor SH
BMC Cancer; 2014 Oct; 14():782. PubMed ID: 25344115
[TBL] [Abstract][Full Text] [Related]
37. Interval lung cancer after a negative CT screening examination: CT findings and outcomes in National Lung Screening Trial participants.
Gierada DS; Pinsky PF; Duan F; Garg K; Hart EM; Kazerooni EA; Nath H; Watts JR; Aberle DR
Eur Radiol; 2017 Aug; 27(8):3249-3256. PubMed ID: 28050695
[TBL] [Abstract][Full Text] [Related]
38. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.
Tailor A; Bourne TH; Campbell S; Okokon E; Dew T; Collins WP
Ultrasound Obstet Gynecol; 2003 Apr; 21(4):378-85. PubMed ID: 12704748
[TBL] [Abstract][Full Text] [Related]
39. [Detection of cancer, sensitivity of the test and sensitivity of the screening program].
Launoy G; Duffy SW; Prevost TC; Bouvier V
Rev Epidemiol Sante Publique; 1998 Nov; 46(5):420-6. PubMed ID: 9864771
[TBL] [Abstract][Full Text] [Related]
40. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
